ReviewDermatology and therapy2019
Hedgehog Pathway Inhibitors and Their Utility in Basal Cell Carcinoma: A Comprehensive Review of Current Evidence.
Review in Dermatology and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 32 citations in OpenAlex.
- Trial
- Glasdegib plus low-dose cytarabine for acute myeloid leukemia: Practical considerations from advanced practitioners and pharmacists.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2021Trial
- Research progress on the Sonic Hedgehog signaling pathway in the central nervous system: Novel insights.Neural regeneration research · 2026Article
- Survey of the impact of BOLT-trial data on oncologists' and dermatologists' decision-making in treating patients with locally advanced basal cell carcinoma.Dermatology reports · 2025Article
- Case report of long-term disease control of recurrent intraoral basal cell carcinoma with vismodegib at two-year follow-up.AME case reports · 2025Article
- Immune microenvironment of basal cell carcinoma and tumor regression following combined PD-1/LAG-3 blockade.Journal for immunotherapy of cancer · 2023Article
- Review
- Management of basal cell carcinoma with pulmonary metastasis.BMJ case reports · 2023Article
- Skin Cancer Research Goes Digital: Looking for Biomarkers within the Droplets.Journal of personalized medicine · 2022Review
- A Conservative Combined Laser Cryoimmunotherapy Treatment vs. Surgical Excision for Basal Cell Carcinoma.Journal of clinical medicine · 2022Article
- Editorial: The Role of DNA Repair Pathways in Resistance to Chemotherapy and Radiotherapy in Cancer.Frontiers in oncology · 2022Article
- Review
- The use of hedgehog antagonists in cancer therapy: a comparison of clinical outcomes and gene expression analyses.Cancer biology & therapy · 2020Article
- Recent Advances in Signaling Pathways Comprehension as Carcinogenesis Triggers in Basal Cell Carcinoma.Journal of clinical medicine · 2020Review
- [Primary basal cell carcinoma of the caruncle].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2019Review
- Hedgehog Pathway Inhibition for the Treatment of Basal Cell Carcinoma.Targeted oncology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Basal cell carcinoma (BCC) is the most commonly diagnosed malignancy in humans, and as such it poses a significant healthcare burden. The majority of BCC cases are amenable to cure by surgical extirpation. However, until recently there have been no good treatment options for a significant minority of advanced BCC cases, including locally advanced BCC and metastatic BCC. The introduction of a novel class of drugs, the Hedgehog pathway inhibitors, into clinical practice has ushered in a new treatment algorithm for the treatment of difficult BCC cases. In this review we present the latest available evidence and discuss areas for further research in this rapidly evolving field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.